Closing the Revolving Door at HHS
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Closing the Revolving Door at HHS
-
Lu par :
-
De :
The Food and Drug Administration plans to ban employees of regulated companies, including drug manufacturers, from serving on the agency's advisory committees. The new policy is aimed at combating industry influence and conflicts of interest, but will it make a difference? We are joined by Genevieve Kanter, an Associate Professor at the USC Price School, who has researched conflicts of interest at the FDA as well as the "revolving door" of people moving between jobs in government and regulated industries.
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment